NOV 1 3 2000

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application

Qingping Jiang et al.

Application No.

09/626,566

Filed

July 27, 2000

For

CHEMILUMINESCENT NOVEL

OF

HYDROLYTIC ENZYMES AND THEIR USE IN ASSAYS

Examiner

Unknown

Attorney's Docket

MOI 17002

Group Art Unit: Unknown

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope Assistant Commissioner for to: Patents, D.C. 20231 on 1/18/00

Arthur S. Morgenstern Registration No. 28,244 Attorney for Applicants

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

It is desired to cite for the record in this application the enclosed references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

[ ] (1) Pursuant to 37 C.F.R. \$1.97(b)(1) and (2), the attached Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above identified application. Accordingly, applicant(s) believe that no fee or statement under 37 C.F.R. § 1.97(e) is required.

Application No. 09/626,566
Filed: July 27, 2000
Group Art Unit: Unknown

- [X] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believe that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [ ] (3) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
  - [ ] a statement under 37 CFR \$1.97(e); or
  - [ ] the fee set forth in \$1.17(p).

## PETITION UNDER 37 CFR \$1.97(d)

[ ] (4) Pursuant to 37 CFR §1.97(d), applicant(s) hereby petition the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(i).

## STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

[ ] (5) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

## STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

[] (6) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

Application No. 09/626,566 Filed: July 27, 2000 Group Art Unit: Unknown

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

By:

Arthur S. Morgenstern Registration No. 28,244 Attorney for Applicants

WEINGARTEN, SCHURGIN,
GAGNEBIN & HAYES LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290 Telecopier: (617) 451-0313

Date: 11/8/00

ASM/jds Enclosure 236100

APPLICATION NO. ATTY. DOCKET NO. U.S. DEPARTMENT OF COMMERCE Form PTO-1449 MOI 17002 09/626,566 PATENT AND TRADEMARK OFFICE (REV. 8-83) ANFORMATION DISCLOSURE CITATION (Use several sheets if necessary) APPLICANT Qingping Jiang et al. GROUP FILING DATE Unknown July 27, 2000 U.S. PATENT DOCUMENTS SUBCLASS FILING DATE **CLASS NAME** DOCUMENT NUMBER DATE **EXAMINER** IF INITIAL APPROPRIATE 387 530 Law et al. 05/17/88 4,745,181 518 436 05/22/90 Chang et al. 4,927,769 700 Bronstein et al. 252 06/05/90 4,931,223 700 252 Schaap 09/25/90 4,959,182 252 700 Schaap 04/02/91 5,004,565 17.3 536 Schaap 5,013,827 05/07/91 18.1 536 Bronstein et al. 05/12/92 5,112,960 4 435 Voyta et al. 09/08/92 5,145,772 FOREIGN PATENT DOCUMENTS **CLASS SUBCLASS** TRANSLATION COUNTRY DOCUMENT NUMBER DATE NO YES C07F9/09 C07D **PCT** 07/12/90 WO 90/07511 277/62 C07D498 491/10 02/03/94 **PCT** WO 94/02486 /10 C12Q1/00 C09K3/0 **PCT** 05/11/94 WO 94/10258 OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) Kazumi Sasamoto et al., A Chemiluminogenic Substrate for N-Acetyl-β-D-glucosaminidase, o-Aminophthalylhydrazido-Nacetyl-β-D-glucosaminide, Chem. Pharm. Bull. 38(5) 1323-1325 (1990). Kazumi Sasamoto et al., A New Chemiluminogenic Substrate for N-Acetyl-β-D-glucosaminidase, 4'-(6'-Diethylaminobenzofuranyl)phthalylhydrazido-N-acetyl-β-D-glucosaminide, Chem. Pharm Bull. 39(2) 411-416 (1991). T. Kinkel et al., Synthesis and Properties of New Luminescent Acridinium-9-carboxylic Acid Derivatives and their Application in Luminescence Immunoasays (LIA), Jour. of Bioluminescence and Chemiluminescence, Vol 4 136-139 (1989) Wolf Dieter Engel et al., CEDIA \* in vitro diagnostics with a novel homogeneous immunoassay technique, Jour. of Immunological Methods, 150 99-102 (1992) DATE CONSIDERED **EXAMINER** \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

WSGH FORM 12

ATTY, DOCKET NO. APPLICATION NO. U.S. DEPARTMENT OF COMMERCE Form PTO-1449 MOI 17002 09/626,566 PATENT AND TRADEMARK OFFICE (REV. 8-83) INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) **APPLICANT** Qingping Jiang et al. FILING DATE **GROUP** July 27, 2000 Unknown **U.S. PATENT DOCUMENTS** CLASS **SUBCLASS** FILING DATE NAME DOCUMENT NUMBER DATE **EXAMINER** IF INITIAL APPROPRIATE 7.91 Kricka 435 5,306,621 04/26/94 Bronstein et al 549 16 07/05/94 5,326,882 Akhavan-Tafti 252 700 5,393,469 02/28/95 700 252 09/19/95 Akhavan-Tafti et al. 5,451,347 501 436 Mattingly et al. 11/21/95 5,468,646 700 Akhavan-Tafti et al. 252 5,484,556 01/16/96 435 12/31/96 Mahant 5,589,328 02/24/98 Akhavan-Tafti et al. 549 218 5,721,370 FOREIGN PATENT DOCUMENTS TRANSLATION **SUBCLASS CLASS** DATE **COUNTRY** DOCUMENT NUMBER YES NO G01N33/ 03/14/96 **PCT** WO 96/07911 535 C07D219 **PCT** WO 97/26245 07/24/97 /00 C07D219 G01N33/533 **PCT** 12/17/98 WO 98/56765 /04 C08D219 G01N33/53 **PCT** 02/25/99 WO 99/09012 /00 OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) Larry J. Kricka, Ultrasensitive Immunoassay Techniques, Clin. Biochem., Vol 26, 325-331 (1993) David Wild et al., Components, Ch. 2 in Wild, The Immonoassay Handbook, (1994), Stockton Press, 4 W. 34th St., NY, NY, 10010, USA A. Paul Schaap et al., Chemical and Enzymatic Triggering of 1,2-Dioxetanes.2: Fluoride-Induced Chemiluminescence from Tert-Butyldimethylsilyloxy-Substituted Dioxetanes, (1987), Tetrahedron Letters Vol. 28, No. 11, 1155-1158 DATE CONSIDERED **EXAMINER** \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance an

WSGH FORM 12

not considered. Include copy of this form with next communication to applicant.

APPLICATION NO. ATTY. DOCKET NO. U.S. DEPARTMENT OF COMMERCE Form PTO-1449 09/626,566 MOI 17002 PATENT AND TRADEMARK OFFICE (REV. 8-83) P ENFORMATION DISCLOSURE CITATION (Use several sheets if necessary) APPLICANT Qingping Jiang et al. GROUP FILING DATE Unknown July 27, 2000 U.S. PATENT DOCUMENTS FILING DATE **SUBCLASS CLASS** NAME DOCUMENT NUMBER DATE IF **EXAMINER** APPROPRIATE INITIAL 700 252 Akhavan-Tafti 06/30/98 5,772,926 549 219 Bronstein et al. 02/09/99 5,869,699 510 549 Schaap et al. 04/06/99 5,892,064 332 549 Akhavan-Tafti et al. 08/10/99 5,936,101 110 548 Akhavan-Tafti 10/12/99 5,965,736 FOREIGN PATENT DOCUMENTS TRANSLATION **SUBCLASS CLASS** COUNTRY DATE DOCUMENT NUMBER NO YES A6K31/435 A61K31/ **PCT** 02/10/00 WO 00/06164 425 G01N33/58 C07D219 **PCT** 02/24/00 WO 00/09487 /04 C07F9/12 C07D321 **EPO** 12/05/90 0 401 001 A2 /00 C12Q1/28 G01N21/ **EPO** 12/09/92 0516948A1 76 A61K C07D **EPO** 03/10/99 EP 0 943 618 A2 31/335 493/04 OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) Brian R. Clark et al., Chapter 8 Enzyme-Linked Immunosorbent Assay (ELISA): Theoretical and Practical Aspects, 167-247 in Maggio, (1980) CRC Press, Inc., 2000 N.W. 24th St., Boca Raton, FL 33431 DATE CONSIDERED \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

WSGH FORM 12

//